PharmaLytica 2021 Hyderabad review.



IIL to produce drug substance for Bharat Biotech’s Covaxin

First batch to be dispatched to Bharat Biotech by July

29th May 2021

To further increase the COVID-19 vaccine manufacturing capacity, Bharat Biotech partnered with Indian Immunologicals Ltd (IIL) to make the drug substance for Covaxin.

IIL has announced its plans to begin the production of drug substance meant for COVID-19 vaccine Covaxin from June 15, and despatch the first batch to Bharat Biotech by July.

K Anand Kumar, Managing Director, IILs in a release said the firm is expected to produce the drug substance initially for two to three million doses per month.

It will be scaled up to seven million later in the year and eventually to 15 million.

The technology transfer process was well underway and IIL has the capabilities and expertise to manufacture inactivated viral vaccines at commercial scale and under biosafety containment, the vaccine maker said.

Kumar said IIL is converting its Karkapatla manufacturing unit into a Biosafety Level -3 (BSL3) facility for the production of the drug substance and also taking up construction of another block.

IIL is also working on another COVID -19 vaccine and the animal trials are underway and is expected to come out next year for human vaccination.




This Website Uses Cookies for Google Analytics, to improve your experience and to show you personalized advertising. By using this website you agree to our COOKIES AND PRIVACY POLICY...Learn More